HER3 expression is also associated with metastatic disease progression and decreased relapse-free survival in patients57, thus, HER3 is an attractive therapeutic target in NSCLC, especially due to its potential functional role in mediating resistance to targeted therapies. Here, ERBB3 is linked to non-small cell lung carcinoma.